Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.
Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.
Study Type
OBSERVATIONAL
Enrollment
60
Taichung Veterans General Hospital
Taichung, Taiwan
RECRUITINGResponse of bevacizumab therapy.
Base on the image after bevacizumab therapy (after recurrence)
Time frame: 3 months after bevacizumab therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.